OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q3 2021. The put-call ratio across all filers is 0.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,247 | -39.1% | 397 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $2,049 | -2.1% | 397 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $2,092 | +87.5% | 397 | 0.0% | 0.00% | +100.0% |
| Q4 2022 | $1,116 | -44.2% | 397 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $2,000 | 0.0% | 397 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $2,000 | 0.0% | 397 | 0.0% | 0.00% | +100.0% |
| Q1 2022 | $2,000 | -33.3% | 397 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $3,000 | -25.0% | 397 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $4,000 | -33.3% | 397 | 0.0% | 0.00% | -25.0% |
| Q2 2021 | $6,000 | -14.3% | 397 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $7,000 | -12.5% | 397 | 0.0% | 0.01% | -14.3% |
| Q4 2020 | $8,000 | -55.6% | 397 | -83.4% | 0.01% | -56.2% |
| Q3 2020 | $18,000 | -10.0% | 2,397 | 0.0% | 0.02% | -27.3% |
| Q2 2020 | $20,000 | +81.8% | 2,397 | 0.0% | 0.02% | +69.2% |
| Q1 2020 | $11,000 | +22.2% | 2,397 | 0.0% | 0.01% | +30.0% |
| Q4 2019 | $9,000 | – | 2,397 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
| Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
| DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
| Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
| Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
| Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
| Covestor Ltd | 60,008 | $316 | 0.28% |
| Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
| EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
| Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |